749 related articles for article (PubMed ID: 29305580)
21. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
[TBL] [Abstract][Full Text] [Related]
22. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
24. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
25. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
26. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
Liu K; Liu S; Zhang W; Jia B; Tan L; Jin Z; Liu Y
Oncol Rep; 2015 Aug; 34(2):1003-10. PubMed ID: 26045065
[TBL] [Abstract][Full Text] [Related]
27. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
Zhang Z; Tan X; Luo J; Yao H; Si Z; Tong JS
Cell Death Dis; 2020 Oct; 11(10):902. PubMed ID: 33097691
[TBL] [Abstract][Full Text] [Related]
28. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
Cheng Z; Ni Q; Qin L; Shi Y
Braz J Med Biol Res; 2021; 54(9):e10390. PubMed ID: 34076140
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
[TBL] [Abstract][Full Text] [Related]
31. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
32. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
Zhang PF; Wang F; Wu J; Wu Y; Huang W; Liu D; Huang XY; Zhang XM; Ke AW
J Cell Physiol; 2019 Mar; 234(3):2788-2794. PubMed ID: 30132868
[TBL] [Abstract][Full Text] [Related]
33. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
34. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
36. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Salvi A; Conde I; Abeni E; Arici B; Grossi I; Specchia C; Portolani N; Barlati S; De Petro G
Mol Cancer; 2013 Dec; 12():162. PubMed ID: 24330766
[TBL] [Abstract][Full Text] [Related]
37. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Azumi J; Tsubota T; Sakabe T; Shiota G
Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
[TBL] [Abstract][Full Text] [Related]
38. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
Shao YY; Chen PS; Lin LI; Lee BS; Ling A; Cheng AL; Hsu C; Ou DL
Br J Cancer; 2022 Jun; 126(12):1806-1814. PubMed ID: 35236936
[TBL] [Abstract][Full Text] [Related]
39. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
[TBL] [Abstract][Full Text] [Related]
40. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
